PIPELINE
ATI-1701
ATI-2307
ATI-1801
ATI-1503
ATI-1501
STRATEGY
Diverse Pipeline
Business Environment
ABOUT US
Leadership
Board of Directors
COLLABORATORS
INVESTORS
Financial Reports
Events and Presentations
Proxy Information
SEDAR Filings
Corporate Governance
Legal Counsel & Auditors
Analyst Coverage
Contact IR
NEWS
News 2022
Archives 2021
Archives 2020
Archives 2019
Archives 2018
Archives 2017
Archives 2016
Media Contact
Media Download Center
CONTACT
CAREERS
Career Opportunities
More
Use tab to navigate through the menu items.
News Highlights
News 2022
Archives 2021
Archives 2020
Archives 2019
Archives 2016-2018
Media Contact
Media Download Center
News Highlights
News 2022
Archives 2021
Archives 2020
Archives 2019
Archives 2016-2018
Media Contact
Media Download Center
May 18, 2022
Appili Therapeutics Announces Pricing of Overnight Marketed Equity Offering
Read More
May 17, 2022
Appili Therapeutics Announces Overnight Marketed Equity Offering
Read More
April 27, 2022
Appili Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
Read More
April 13, 2022
Appili Therapeutics Announces New Late-Stage Clinical Program ATI-1801 to Treat Cutaneous Leishmaniasis
Read More
March 29, 2022
Appili Therapeutics Announces Non-Convertible Secured Loan of US$3.6 Million and License and Distribution Agreement with Long Zone Holdings
Read More
March 9, 2022
Appili Therapeutics to Present Live via Webcast at OTC Markets Virtual Life Sciences Investor Forum
Read More
February 28, 2022
Appili Therapeutics Announces Over US$10 Million in New Funding from US Department of Defense for Biodefense Vaccine Candidate ATI-1701
Read More
February 14, 2022
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2022
Read More
February 8, 2022
Appili Therapeutics Expands ATI-1501 Commercial Agreement with Partner Saptalis Pharmaceuticals
Read More